Advertisement
YOU ARE HERE: LAT HomeCollectionsRibavirin Drug
IN THE NEWS

Ribavirin Drug

FEATURED ARTICLES
BUSINESS
April 3, 2001 | MARC BALLON, TIMES STAFF WRITER
After a five-year investigation, a federal grand jury has decided against indicting the chairman and other executives of ICN Pharmaceuticals Inc. over claims they misled investors about prospects for its prize drug, the company said Monday.
ARTICLES BY DATE
BUSINESS
April 2, 2003 | Denise Gellene, Times Staff Writer
ICN Pharmaceuticals Inc. shares soared Tuesday on news that one of the company's experimental drugs is being used to treat severe acute respiratory syndrome, or SARS, the mysterious respiratory illness from Asia. ICN of Costa Mesa rose $1.59 to $10.50, a gain of 18% on the New York Stock Exchange. Despite the jump, ICN trades at one-third the price of its 52-week high of $31.73 last April. The firm said it was supplying an intravenous form of its antiviral drug ribavirin as a treatment for SARS.
Advertisement
NEWS
October 21, 1987 | LESLIE BERKMAN, Times Staff Writer
The Food and Drug Administration has given ICN Pharmaceuticals of Costa Mesa permission to begin new clinical trials of ribavirin, a drug that the company hopes will be effective in combatting early-stage AIDS. In doing so, FDA spokesman Brad Stone said, the agency has lifted "a de facto clinical hold" on further human testing of ICN's proprietary drug ribavirin. The test ban was imposed because of previous FDA concerns about the drug's safety.
BUSINESS
May 23, 2001 | Bloomberg News
ICN Pharmaceutical Inc.'s prize drug ribavirin works better with a new Roche Holding product in treating hepatitis C than it does with its current drug combination to treat the liver disease, according to a university research report released Tuesday. Patients responded to the once-a-week combination of Roche's Pegasys and ribavirin 56% of the time, compared with a response rate of 45% for Rebetron, a Schering-Plough Inc.
NEWS
October 8, 1991 | GREGORY CROUCH, TIMES STAFF WRITER
The Securities and Exchange Commission on Monday sued ICN Pharmaceuticals and its Viratek Inc. subsidiary for alleged securities fraud, claiming that the firms knowingly misled the public about Viratek's ribavirin drug and its effectiveness in fighting the AIDS virus. Without admitting or denying any wrongdoing, the companies immediately settled the suit by signing a consent decree in which they agreed not to violate securities laws in future.
BUSINESS
September 23, 1997 | BARBARA MARSH, TIMES STAFF WRITER
ICN Pharmaceuticals Inc.'s stock shot up Monday on news that tests showed its drug ribavirin may be effective in treating hepatitis when combined with a drug manufactured by giant Schering-Plough Corp. ICN stock climbed $6.06 a share to $49.88 in heavy trading on the New York Stock Exchange after hitting a 52-week high of $52.88 earlier in the session. Nearly 2.7 million shares changed hands, 10 times the stock's recent average daily volume.
BUSINESS
July 8, 1990 | LESLIE BERKMAN and GREGORY CROUCH, TIMES STAFF WRITERS
Just days before the sixth international conference on AIDS opened in San Francisco last month, something peculiar was going on at ICN Pharmaceuticals Inc. The company's stock started a mysterious trek upward in unusually heavy trading on the New York Stock Exchange, climbing 86% in just 12 days.
BUSINESS
March 1, 1990 | LESLIE BERKMAN, TIMES STAFF WRITER
ICN Pharmaceuticals said Wednesday that it has ceased efforts to obtain approval to market ribavirin in the United States as a remedy against the AIDS virus and took a $71-million writedown in the fourth quarter, largely as a result of that decision. The Costa Mesa-based drug company reported a loss of $82 million for fiscal 1989 ended Nov. 30 on sales of $185.5 million, contrasted with earnings of $17.8 million on sales of $166.3 million in fiscal 1988. In the fourth quarter ended Nov.
BUSINESS
December 10, 1998 | From Bloomberg News
Schering-Plough Corp. and ICN Pharmaceuticals Inc. won regulatory approval Wednesday to sell their combination hepatitis C treatment to a wider group of patients. The Food and Drug Administration approved the combination therapy known as Rebetron for use in patients who haven't been treated already with standard hepatitis-fighting drugs. The wider use should boost sales for Schering-Plough, the eighth biggest U.S. drug maker, and Costa Mesa-based ICN, Eastern Europe's largest drug maker.
NEWS
May 5, 1998 | From Times Wire Reports
A combination of two powerful antiviral drugs that proved 10 times better at treating liver-destroying hepatitis C than standard therapy won the cautious backing of government advisors. It's a complicated treatment that lasts six months: taking six capsules every day of an experimental drug called ribavirin, plus the standard therapy of interferon injections three times a week.
BUSINESS
April 3, 2001 | MARC BALLON, TIMES STAFF WRITER
After a five-year investigation, a federal grand jury has decided against indicting the chairman and other executives of ICN Pharmaceuticals Inc. over claims they misled investors about prospects for its prize drug, the company said Monday.
BUSINESS
January 23, 2001 | From Bloomberg News
Schering-Plough Corp. and Enzon Inc. have won U.S. Food and Drug Administration approval to sell Peg-Intron, a hepatitis C drug that analysts say could have more than $2 billion in annual sales. The injectable drug is a once-weekly version of Schering-Plough's Intron A, the world's top-selling hepatitis medication, and is considered by analysts to be key to increased sales for Schering-Plough over the next five years.
BUSINESS
December 10, 1998 | From Bloomberg News
Schering-Plough Corp. and ICN Pharmaceuticals Inc. won regulatory approval Wednesday to sell their combination hepatitis C treatment to a wider group of patients. The Food and Drug Administration approved the combination therapy known as Rebetron for use in patients who haven't been treated already with standard hepatitis-fighting drugs. The wider use should boost sales for Schering-Plough, the eighth biggest U.S. drug maker, and Costa Mesa-based ICN, Eastern Europe's largest drug maker.
NEWS
May 5, 1998 | From Times Wire Reports
A combination of two powerful antiviral drugs that proved 10 times better at treating liver-destroying hepatitis C than standard therapy won the cautious backing of government advisors. It's a complicated treatment that lasts six months: taking six capsules every day of an experimental drug called ribavirin, plus the standard therapy of interferon injections three times a week.
BUSINESS
May 5, 1998 | BARBARA MARSH, TIMES STAFF WRITER
A key government panel recommended Monday that ICN Pharmaceuticals Inc.'s drug ribavirin be approved in combination with another drug for treating patients who suffer relapses of the severe liver ailment hepatitis C. If the U.S. Food and Drug Administration accepts the recommendation--as it usually does--ICN will clear a major hurdle in its lengthy effort to persuade regulators to approve the drug for multiple uses.
BUSINESS
September 23, 1997 | BARBARA MARSH, TIMES STAFF WRITER
ICN Pharmaceuticals Inc.'s stock shot up Monday on news that tests showed its drug ribavirin may be effective in treating hepatitis when combined with a drug manufactured by giant Schering-Plough Corp. Shares of Costa Mesa-based ICN climbed $6.06 to close at $49.88 in heavy trading on the New York Stock Exchange, after hitting a 52-week high of $52.88 earlier in the session. Nearly 2.7 million shares changed hands, 10 times the stock's recent average daily volume.
BUSINESS
September 23, 1997 | BARBARA MARSH, TIMES STAFF WRITER
ICN Pharmaceuticals Inc.'s stock shot up Monday on news that tests showed its drug ribavirin may be effective in treating hepatitis when combined with a drug manufactured by giant Schering-Plough Corp. Shares of Costa Mesa-based ICN climbed $6.06 to close at $49.88 in heavy trading on the New York Stock Exchange, after hitting a 52-week high of $52.88 earlier in the session. Nearly 2.7 million shares changed hands, 10 times the stock's recent average daily volume.
BUSINESS
September 23, 1997 | BARBARA MARSH, TIMES STAFF WRITER
ICN Pharmaceuticals Inc.'s stock shot up Monday on news that tests showed its drug ribavirin may be effective in treating hepatitis when combined with a drug manufactured by giant Schering-Plough Corp. ICN stock climbed $6.06 a share to $49.88 in heavy trading on the New York Stock Exchange after hitting a 52-week high of $52.88 earlier in the session. Nearly 2.7 million shares changed hands, 10 times the stock's recent average daily volume.
BUSINESS
September 8, 1995 | DAN MARGOLIS
ICN Pharmaceuticals Inc. said Thursday that its deal with industry giant Schering-Plough for the international marketing of ICN's prized antiviral drug, ribavirin, has cleared an antitrust hurdle. The Federal Trade Commission has given ICN approval to proceed with the marketing arrangement. Schering-Plough will direct clinical efforts to prove that ICN's drug, named Virazole, works with the New Jersey company's interferon drug to treat the highly contagious liver ailment hepatitis C.
Los Angeles Times Articles
|